Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer

Overview

Journal Cell

Publisher Cell Press

Specialty Cell Biology

Date 2016 Jul 4

PMID 27372738

Citations 544

Authors

Hui Zhang

Tao Liu

Zhen Zhang

Samuel H Payne

Bai Zhang

Jason E McDermott

Jian-Ying Zhou

Vladislav A Petyuk

Li Chen

Debjit Ray

Shisheng Sun

Feng Yang

Lijun Chen

Jing Wang

Punit Shah

Seong Won Cha

Paul Aiyetan

Sunghee Woo

Yuan Tian

Marina A Gritsenko

Therese R Clauss

Caitlin Choi

Matthew E Monroe

Stefani Thomas

Song Nie

Chaochao Wu

Ronald J Moore

Kun-Hsing Yu

David L Tabb

David Fenyo

Vineet Bafna

Yue Wang

Henry Rodriguez

Emily S Boja

Tara Hiltke

Robert C Rivers

Lori Sokoll

Heng Zhu

Ie-Ming Shih

Leslie Cope

Akhilesh Pandey

Bing Zhang

Michael P Snyder

Douglas A Levine

Richard D Smith

Daniel W Chan

Karin D Rodland

Affiliations

Soon will be listed here.

Abstract

To provide a detailed analysis of the molecular components and underlying mechanisms associated with ovarian cancer, we performed a comprehensive mass-spectrometry-based proteomic characterization of 174 ovarian tumors previously analyzed by The Cancer Genome Atlas (TCGA), of which 169 were high-grade serous carcinomas (HGSCs). Integrating our proteomic measurements with the genomic data yielded a number of insights into disease, such as how different copy-number alternations influence the proteome, the proteins associated with chromosomal instability, the sets of signaling pathways that diverse genome rearrangements converge on, and the ones most associated with short overall survival. Specific protein acetylations associated with homologous recombination deficiency suggest a potential means for stratifying patients for therapy. In addition to providing a valuable resource, these findings provide a view of how the somatic genome drives the cancer proteome and associations between protein and post-translational modification levels and clinical outcomes in HGSC. VIDEO ABSTRACT.

Citing Articles

Advancements in proteogenomics for preclinical targeted cancer therapy research.

Suo Y, Song Y, Wang Y, Liu Q, Rodriguez H, Zhou H Biophys Rep. 2025; 11(1):56-76.

PMID: 40070661 PMC: 11891078. DOI: 10.52601/bpr.2024.240053.

Learning directed acyclic graphs for ligands and receptors based on spatially resolved transcriptomic data of ovarian cancer.

Chowdhury S, Ferri-Borgogno S, Yang P, Wang W, Peng J, C Mok S Brief Bioinform. 2025; 26(2).

PMID: 40062614 PMC: 11891659. DOI: 10.1093/bib/bbaf085.

Proteomic and metabolomic insights into the impact of topping treatment on cigar tobacco.

Guo D, Gao H, Yan T, Xia C, Lin B, Xiang X Front Plant Sci. 2025; 15:1425154.

PMID: 40052119 PMC: 11882365. DOI: 10.3389/fpls.2024.1425154.

Machine Learning-Enhanced Extraction of Protein Signatures of Renal Cell Carcinoma from Proteomics Data.

Liu H, Ma Z, Lih T, Chen L, Hu Y, Wang Y bioRxiv. 2025; .

PMID: 40027663 PMC: 11870591. DOI: 10.1101/2025.02.17.638651.

Sonication-assisted protein extraction improves proteomic detection of membrane-bound and DNA-binding proteins from tumor tissues.

Li Q, Lih T, Clark D, Chen L, Schnaubelt M, Zhang H Nat Protoc. 2025; .

PMID: 39962197 DOI: 10.1038/s41596-024-01113-9.

References

Cai R, Cueto M, Xu H, Cohen D . HDAC1, a histone deacetylase, forms a complex with Hus1 and Rad9, two G2/M checkpoint Rad proteins. J Biol Chem. 2000; 275(36):27909-16. DOI: 10.1074/jbc.M000168200. View

Woodbine L, Gennery A, Jeggo P . The clinical impact of deficiency in DNA non-homologous end-joining. DNA Repair (Amst). 2014; 16:84-96. DOI: 10.1016/j.dnarep.2014.02.011. View

Vang R, Levine D, Soslow R, Zaloudek C, Shih I, Kurman R . Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. Int J Gynecol Pathol. 2015; 35(1):48-55. PMC: 4696053. DOI: 10.1097/PGP.0000000000000207. View

Yu G, Zhang B, Bova G, Xu J, Shih I, Wang Y . BACOM: in silico detection of genomic deletion types and correction of normal cell contamination in copy number data. Bioinformatics. 2011; 27(11):1473-80. PMC: 3102226. DOI: 10.1093/bioinformatics/btr183. View

Vogel C, Marcotte E . Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012; 13(4):227-32. PMC: 3654667. DOI: 10.1038/nrg3185. View

Gong F, Miller K . Mammalian DNA repair: HATs and HDACs make their mark through histone acetylation. Mutat Res. 2013; 750(1-2):23-30. DOI: 10.1016/j.mrfmmm.2013.07.002. View

Kuo K, Guan B, Feng Y, Mao T, Chen X, Jinawath N . Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res. 2009; 69(9):4036-42. PMC: 2782554. DOI: 10.1158/0008-5472.CAN-08-3913. View

Marguerat S, Schmidt A, Codlin S, Chen W, Aebersold R, Bahler J . Quantitative analysis of fission yeast transcriptomes and proteomes in proliferating and quiescent cells. Cell. 2012; 151(3):671-83. PMC: 3482660. DOI: 10.1016/j.cell.2012.09.019. View

Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi Z . Proteogenomic characterization of human colon and rectal cancer. Nature. 2014; 513(7518):382-7. PMC: 4249766. DOI: 10.1038/nature13438. View

10.

Mielcarek M, Zielonka D, Carnemolla A, Marcinkowski J, Guidez F . HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements. Front Cell Neurosci. 2015; 9:42. PMC: 4338808. DOI: 10.3389/fncel.2015.00042. View

11.

Zhang B, Li H, Riggins R, Zhan M, Xuan J, Zhang Z . Differential dependency network analysis to identify condition-specific topological changes in biological networks. Bioinformatics. 2008; 25(4):526-32. PMC: 2642641. DOI: 10.1093/bioinformatics/btn660. View

12.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

13.

Kislinger T, Cox B, Kannan A, Chung C, Hu P, Ignatchenko A . Global survey of organ and organelle protein expression in mouse: combined proteomic and transcriptomic profiling. Cell. 2006; 125(1):173-86. DOI: 10.1016/j.cell.2006.01.044. View

14.

Collins B, Gillet L, Rosenberger G, Rost H, Vichalkovski A, Gstaiger M . Quantifying protein interaction dynamics by SWATH mass spectrometry: application to the 14-3-3 system. Nat Methods. 2013; 10(12):1246-53. DOI: 10.1038/nmeth.2703. View

15.

Pradeep S, Kim S, Wu S, Nishimura M, Chaluvally-Raghavan P, Miyake T . Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014; 26(1):77-91. PMC: 4100212. DOI: 10.1016/j.ccr.2014.05.002. View

16.

Creighton C, Hernandez-Herrera A, Jacobsen A, Levine D, Mankoo P, Schultz N . Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS One. 2012; 7(3):e34546. PMC: 3315571. DOI: 10.1371/journal.pone.0034546. View

17.

Barres V, Ouellet V, Lafontaine J, Tonin P, Provencher D, Mes-Masson A . An essential role for Ran GTPase in epithelial ovarian cancer cell survival. Mol Cancer. 2010; 9:272. PMC: 2964620. DOI: 10.1186/1476-4598-9-272. View

18.

Gadducci A, Lanfredini N, Sergiampietri C . Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research. Crit Rev Oncol Hematol. 2015; 96(1):113-28. DOI: 10.1016/j.critrevonc.2015.05.009. View

19.

MacKay H, Hirte H, Colgan T, Covens A, MacAlpine K, Grenci P . Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer. 2010; 46(9):1573-9. PMC: 3244274. DOI: 10.1016/j.ejca.2010.02.047. View

20.

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View